VALIANTLAB · Valiant Laboratories Ltd · Biotechnology & Drugs
VALIANTLAB · Valiant Laboratories Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
16.2% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹115 Cr
Revenue YoY
PAT YoY
+1059.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.1
P/S (TTM)
2.3
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| VALIANTLAB (this stock) | 21.1 | 2.1 | +5.2% | +5.2% | 0.15 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedValiant Laboratories Limited, a pharmaceutical company specializing in manufacturing high-quality Active Pharmaceutical Ingredients (APIs), particularly in the Paracetamol API segment, reported significant revenue growth in FY2025-26. The company emphasized its strong domestic sourcing and supply chain resilience, commitment to research and innovation through Valiant Advanced Sciences Pvt. Ltd., and robust governance practices. The report highlighted the impact of global economic factors, including rising commodity prices and geopolitical tensions, on the pharmaceutical industry. The company also noted the importance of government initiatives and the reconfiguration of global supply chains as opportunities for growth.
- Focus on manufacturing high-quality Paracetamol API with a strong domestic presence
- Commitment to research and innovation through Valiant Advanced Sciences Pvt. Ltd.
- Robust governance and ethical business practices
- Emphasis on domestic sourcing to mitigate global supply chain risks
- Strategic response to global supply chain reconfigurations and government incentives
Key takeaway: Valiant Laboratories Limited is positioning itself as a reliable supplier of high-quality Paracetamol API, leveraging domestic sourcing, innovation, and strong governance to navigate global challenges and capitalize on industry growth opportunities.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesRecent (last 12 months)
The company received a fine of ₹11,800 (inclusive of GST) from National Stock Exchange of India Limited for delay in prior intimation of the Rights Issue Committee Meeting held on July 15, 2025.
Earlier (1-3 years ago)
The company received a regulatory order dated September 30, 2024 from the Judicial Magistrate First Class, Palghar (II Court), for failure to prevent static charge accumulation leading to a plant operator's death, resulting in a penalty of ₹30,000 each on the occupier and Factory Manager under Maharashtra Factories Rules and the Factories Act.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has a corporate guarantee of ₹100 crores provided by VLL on behalf of VASPL, of which ₹44.95 crores has been availed as of March 26, 2026. Future cash outflows related to pending legal matters are uncertain and depend on judgments or decisions from various forums.
Earlier (1-3 years ago)
The company has a contingent liability of Rs.100 crores from a corporate guarantee given by VLL on behalf of VASPL, of which Rs.61.80 crores has been availed as of March 25.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has disclosed related party transactions as required by Ind AS 24, including entities like Dhanvallabh Ventures LLP, Valiant Organics Limited, and Valiant Advanced Sciences Private Limited, which are related through holding and subsidiary relationships.
Earlier (1-3 years ago)
The company approved a material related party transaction with Valiant Organics Limited for the sale/purchase of goods/services, as per SEBI regulations and the company's policy.
Management & Board Governance
2 occurrencesRecent (last 12 months)
Ms Prajakta Patil resigned as Executive Director & Chief Financial Officer effective June 15, 2026.
Earlier (1-3 years ago)
Ms Prajakta Patil resigned as Company Secretary effective June 15, 2025.